Microcap Ledger Heron Therapeutics, Inc. /de/ $HRTX
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- San Diego, CA
- Fiscal year end
- December 31
- Shares outstanding
- 189,852,307 [10-Q 2026-08-10]
What the company doesAI summary of filing
Heron Therapeutics is a commercial-stage biotechnology company that develops and commercializes pharmaceutical products for acute care and oncology patients. The company's marketed products include ZYNRELEF (bupivacaine and meloxicam extended-release solution) for postsurgical pain, APONVIE (aprepitant injectable emulsion) for postoperative nausea and vomiting, CINVANTI (aprepitant injectable emulsion) for chemotherapy-induced nausea and vomiting, and SUSTOL (granisetron extended-release injection) for nausea and vomiting associated with chemotherapy. Heron generates revenue from product sales through specialty distributors and wholesalers to hospitals and healthcare providers in the United States, and relies on third-party manufacturers for production of all commercial and clinical supplies. [10-K 2026-02-26]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $72.38M | −$13.60M | −$3.75M | $20.72M | [10-Q 2026-08-10] |
| FY ended Dec 2025 | $154.90M | −$20.00M | −$27.59M | $28.65M | [10-K 2026-02-26] |
| FY ended Dec 2024 | $144.28M | −$14.00M | −$22.53M | $25.80M | [10-K 2026-02-26] |
- Quarterly cash burn
- −$1.88M
- Cash runway Estimate
- ~33.1 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-07 | 152,094,912 | [10-Q 2024-11-12] |
| 2025-02-13 | 152,329,588 | [10-K 2025-02-27] |
| 2025-05-01 | 152,563,634 | [10-Q 2025-05-06] |
| 2025-07-31 | 153,291,798 | [10-Q 2025-08-08] |
| 2025-10-30 | 183,362,522 | [10-Q 2025-11-04] |
| 2026-02-13 | 188,537,136 | [10-K 2026-02-26] |
| 2026-05-06 | 189,279,369 | [10-Q 2026-05-11] |
| 2026-08-05 | 189,852,307 | [10-Q 2026-08-10] |
- Shelf registration
- S-3 filed 2025-09-09; declared effective 2025-09-16 [S-3 2025-09-09]
Listing status
Current status: 1 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-06-25. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2026-06-25 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-06-25] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-08-06 | Hensley Mark Earl | exercise | 31,250 | — | [4 2026-08-10] |
| 2026-08-06 | Hensley Mark Earl | other | 8,888 | $0.50 | [4 2026-08-10] |
| 2026-07-31 | Hensley Mark Earl | exercise | 11,769 | — | [4 2026-08-03] |
| 2026-07-31 | Forbes William P | exercise | 11,694 | — | [4 2026-08-03] |
| 2026-07-31 | Forbes William P | other | 3,326 | $0.50 | [4 2026-08-03] |
| 2026-07-31 | Duarte Ira | exercise | 11,694 | — | [4 2026-08-03] |
| 2026-07-31 | Duarte Ira | other | 3,326 | $0.50 | [4 2026-08-03] |
| 2026-07-31 | Collard Craig A | exercise | 34,789 | — | [4 2026-08-03] |
| 2026-07-30 | Forbes William P | exercise | 11,769 | — | [4 2026-08-03] |
| 2026-07-30 | Forbes William P | other | 3,348 | $0.50 | [4 2026-08-03] |
| 2026-07-30 | Duarte Ira | exercise | 13,535 | — | [4 2026-08-03] |
| 2026-07-30 | Duarte Ira | other | 3,850 | $0.50 | [4 2026-08-03] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-29 | 8-K | Material agreement entered |
| 2026-08-14 | 8-K | Material agreement entered; Change to security holder rights |
| 2026-08-10 | 10-Q | Quarterly report |
| 2026-08-10 | 8-K | Results of operations |
| 2026-06-25 | 8-K | Listing notice or transfer |
| 2026-06-16 | 8-K | Shareholder vote results |
| 2026-06-02 | 8-K | Other events |
| 2026-05-13 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-05-11 | 10-Q | Quarterly report |
| 2026-05-11 | 8-K | Results of operations |
| 2026-04-30 | DEF 14A | Proxy statement |
| 2026-04-20 | PRE 14A | Proxy statement |
Alerts for $HRTX
Email me when Heron Therapeutics, Inc. /de/ files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.